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hy We Do What We Do?
aking Sense of Antithrombotic Therapy in
atients With Non–ST-Segment Elevation
yocardial Infarction Undergoing
ercutaneous Coronary Intervention*
orin J. Brener, MD
rooklyn, New York
“Humanity’s greatest advances are not in its discoveries—
but in how those discoveries are applied.”
—Bill Gates (honorary doctorate acceptance speech,
Harvard, June, 2007)
CEO and President of Microsoft
ew if any entities in medicine have been investigated in
uch detail, in numerous randomized clinical trials and in
rospective national registries, as non–ST-segment eleva-
ion myocardial infarction (NSTEMI). A well-understood
athophysiology (1), effective pharmacological interventions
hat can reverse it (2), and complementary mechanical
nterventions that repair the damage (3) have contributed to
his abundance of information, probably envied by many
ther specialties. Yet, many reports have alerted us to the
izable chasm between what we know and what we do
4–6). Specifically, although patients at the highest risk of
dverse events seem to benefit the most from aggressive
harmacological and revascularization interventions, these
See page 669
re frequently reserved for the healthier and more stable
atients with NSTEMI. Is it because providers do not know
he facts or is it because they view differently the immediate
isks versus the putative long-term benefits? After all, there
s good empiric evidence that application of guideline-
ecommended therapy improves outcomes in this high-risk
opulation (7). Non–ST-segment elevation myocardial in-
arction provides a fertile ground for this kind of investiga-
ion, because the 2 most feared complications of this
ondition—significant bleeding and ischemic complica-
ions, particularly death—share so many risk factors in
Editorials published in JACC: Cardiovascular Interventions reflect the views of the
uthors and do not necessarily represent the views of JACC: Cardiovascular Interven-
ions or the American College of Cardiology.c
From the Department of Cardiology, New York Methodist Hospital, Brooklyn,
ew York.ommon (8,9). The older patients, usually women, with
iabetes mellitus, congestive heart failure, anemia, and renal
ysfunction, are at the highest risk of ischemic complica-
ions and could benefit the most from aggressive antithrom-
otic therapy and revascularization. Yet, some of the exact
herapies addressing these impending complications are
ssociated in these very patients with increased risk of
leeding, which by itself adversely affects prognosis (10). A
eal conundrum (11)!
In this issue of JACC: Cardiovascular Interventions, Lopes
t al. (12) tackle this difficult task in a laudable fashion.
ith the successor to the CRUSADE (Can Rapid risk
tratification of Unstable angina patients Suppress ADverse
utcomes with Early implementation of the ACC/AHA
uidelines) registry, the ACTION (Acute Coronary Treat-
ent and Intervention Outcomes Network) registry, the
nvestigators evaluated the implementation of guidelines
ith respect to antithrombotic regimens in patients with
STEMI undergoing percutaneous coronary intervention
n 2007. At 217 hospitals, 11,805 patients were analyzed
ccording to type of antithrombin therapy received: heparin
lone, bivalirudin alone, or each of them in conjunction with
glycoprotein IIb/IIIa receptor inhibitor (GPI). A few
onths after the publication of the ACUITY (Acute
atheterization and Urgent Intervention Triage strategY)
rial (13) and before the 2007 update of guidelines for
STEMI management (14), 64% of patients were treated
ith the combination of heparin and GPI, 8% were treated
ith bivalirudin and GPI, and 12% and 16% had heparin or
ivalirudin alone, respectively. Despite receiving bivalirudin
nly during the procedure, patients were assigned to this
roup even though 91% of them received heparin up to 1 h
efore the procedure. After a reasonable (albeit incomplete)
ffort to correct for baseline differences between the groups,
ajor bleeding—according to the CRUSADE defini-
ion—was 50% less common in patients receiving bivaliru-
in or heparin alone compared with those receiving a
PI-based regimen. Mortality was rare in all groups (ap-
roximately 1%) and numerically lowest in the bivalirudin
lone group. The important findings of this report are not in
he outcomes but in the process of allocation of therapies
nd their timing.
As compared with patients receiving a GPI-based regi-
en, the patients receiving heparin or bivalirudin mono-
herapy were older by 5 years and more often female. Their
istory more often included heart failure, diabetes mellitus,
rior revascularization, peripheral vascular disease, stroke,
nd myocardial infarction. Their kidney function was worse,
heir hematocrit was lower, and they waited longer before
ercutaneous coronary intervention. In other words, they
ere more likely to be in the moderate and high risk tertiles
or in-hospital death. Equally important, however, their risk
f bleeding was also higher because of these baseline
haracteristics. It is this risk that likely influenced their
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679roviders not to prescribe for them a GPI-based regimen.
nfortunately, it also probably dictated the lower incidence
f administration of clopidogrel. Yet, despite a higher
aseline risk for death and bleeding, administration of
eparin or bivalirudin alone (the latter preceded almost
lways by heparin) resulted in lower crude and adjusted rates
f bleeding and even mortality, particularly in the
ivalirudin-treated patients, compared with the guideline-
ecommended combination of heparin and GPI.
Are the guidelines wrong? Are the providers correctly
ssessing the risk/benefit ratio and selecting patients for the
ppropriate therapies? It is difficult to answer these ques-
ions with certainty. As the authors appropriately recognize,
any limitations make these retrospective analyses of vol-
ntary, minimally audited national registries complex. Why
id the providers leave at least 25% of the patients on aspirin
nd heparin (or bivalirudin) alone, without clopidogrel or
PI, despite a Class I recommendation to use 1 of the latter
agents in these patients before angiography? It is unlikely
hat the physicians calculated the CRUSADE bleeding and
eath scores before therapy assignment, and thus it seems
hat the perceived bleeding risk was more important in
etermining therapy than was the ischemic risk. The use of
eparin and GPI, associated with most bleeding, was
qually prevalent among patients with high and low death
isk but was lower among those with high bleeding risk,
egardless of death risk. Physicians seem to perceive
ntuitively the risk for immediate bleeding and try to
inimize it. They seem to have less regard for the risk of
ater death or other ischemic events and for the possibility
hat minimizing bleeding might in fact contribute to
schemic complications.
Altogether, these findings confirm the overall results of
he ACUITY trial. Patients with moderate- and high-risk
on–ST-segment elevation acute coronary syndrome
reated with bivalirudin alone (with preceding heparin in
ost) have a lower rate of major bleeding and equivalent or
etter rates of death than patients treated with heparin and
PI. These observations should lead us to encourage
hysicians to calculate bleeding and death risk scores to
ailor therapy judiciously. It is time to know the “why” as
ell as the “how.”
eprint requests and correspondence: Dr. Sorin J. Brener, New
ork Methodist Hospital, Cardiology, 506 6th Street, Brooklyn,
ew York 11215. E-mail: sjb9005@nyp.org.
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